Odevixibat (Bylvay) is an ileal bile acid transporter (IBAT) inhibitor, mainly indicated for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). It is a prescription drug and must be used strictly in accordance with the doctor's instructions.

Pramipexole is a non-ergot dopamine receptor agonist, mainly used for the treatment of Parkinson's disease (PD) and moderate-to-severe primary restless legs syndrome (RLS). Its efficacy and effectiveness are highly dependent on individualized medication regimens, and the dosage needs to be adjusted according to the patient's renal function, comorbidities, and treatment response.

Pomalidomide is a thalidomide analog developed by Bristol-Myers Squibb.

Pramipexole is a non-ergot dopamine receptor agonist, primarily indicated for the treatment of Parkinson's disease and moderate-to-severe primary restless legs syndrome (RLS). Due to its unique pharmacological effects and strict medication requirements, patients must pay special attention to the legitimacy of purchase channels, identification of genuine vs. counterfeit drugs, and relevant contraindications when purchasing this medication.

Eliglustat (Cerdelga) is a selective glucosylceramide synthase inhibitor indicated for the long-term treatment of Type 1 Gaucher disease (GD1) in adults. Its efficacy and effectiveness are highly dependent on an individual's metabolic status and comorbidities. Therefore, it is essential to strictly follow the dosing regimen based on CYP2D6 metabolic phenotype and adjust the dose for special populations.

Pomalidomide is a thalidomide analog classified as an immunomodulator. It is indicated for the treatment of multiple myeloma (MM) and Kaposi sarcoma (KS). Its use must strictly adhere to the principle of individualization, and attention should be paid to contraindications such as embryotoxicity and thromboembolic risk.

Pomalidomide is a thalidomide analog and belongs to the class of immunomodulators. It is indicated for the treatment of multiple myeloma (MM) and Kaposi's sarcoma (KS). Its use must strictly adhere to the principle of individualization, and attention should be paid to contraindications such as embryotoxicity and thromboembolic risk.

Odevixibat (Bylvay) is a selective ileal bile acid transporter (IBAT) inhibitor, indicated for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Odevixibat (Bylvay) is an ileal bile acid transporter (IBAT) inhibitor. It is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC)-related pruritus in patients aged 3 months and older, as well as cholestatic pruritus associated with Alagille syndrome (ALGS) in patients aged 12 months and older.

Odevixibat (Bylvay) is an ileal bile acid transporter (IBAT) inhibitor used for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). Its efficacy and safety require individualized adjustment based on the patient’s age, body weight, and disease type.